•High ORR and CR in relapsed or refractory LG,F, T NHL
•Efficacy in Rituxan® nonresponders
•Well tolerated; hematologic toxicity is dose limiting
•Patient selection is important to ensure safety
•Regimencompleted in 7
to 9 days in an OP setting
•Universal Precautions = Zevalin Precautions
•Team approach to therapy
Zevalin:
Most Common Nonhematologic Adverse Events
Coiffier
et al. N Engl J Med. 2002;
346:235
CHOP:Most Common
Nonhematologic Adverse Events
Coiffier
et al. N Engl J Med. 2002;
346:235
Zevalin
Reimbursement
•Refer professionals to RESULTS™ hotline for questions on
current billing or reimbursement and to pre-qualify patients •RESULT(Reimbursement Support
Line-Trained Specialists)
